Global Human Platelet Lysate Market Research Report 2022

Human platelet lysate (HPL) is a non-animal derived cell culture growth supplement obtained from blood platelets after freezing and thawing. HPL contains abundant growth factors and cytokines necessary for cell growth and proliferation. Platelet lysate can be used as a source of growth factors to replace bovine serum in cell culture medium. Replacing bovine serum with HPL allows expansion and clinical grade production of functional mesenchymal stromal cells by removing the risk of xenogeneic immune reactions and transmission of bovine prion and viral pathogens.
Due to the COVID-19 pandemic, the global Human Platelet Lysate market size is estimated to be worth US$ 2515 million in 2021 and is forecast to a readjusted size of US$ 2913.3 million by 2028 with a CAGR of 2.1% during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Human Platelet Lysate market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Human Platelet Lysate landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Heparin accounting for % of the Human Platelet Lysate global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Contract Research Organizations segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of Human Platelet Lysate include Mill Creek Life Sciences, Merck & Co., Inc, STEMCELL Technologies Inc, AventaCell BioMedical, Compass Biomedical, Inc, Macopharma SA, Trinova Biochem GmbH, PL BioScience GmbH and Cook Regentec. etc. In terms of revenue, the global 3 largest players have a % market share of Human Platelet Lysate in 2021.
This report focuses on Human Platelet Lysate volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Human Platelet Lysate market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Human Platelet Lysate Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Heparin
Heparin Free
Segment by Application
Contract Research Organizations
Academic & Research Institutes
Pharmaceutical Companies
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Mill Creek Life Sciences
Merck & Co., Inc
STEMCELL Technologies Inc
AventaCell BioMedical
Compass Biomedical, Inc
Macopharma SA
Trinova Biochem GmbH
PL BioScience GmbH
Cook Regentec